首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1381740篇
  免费   101395篇
  国内免费   6120篇
耳鼻咽喉   20174篇
儿科学   40924篇
妇产科学   39571篇
基础医学   192032篇
口腔科学   40728篇
临床医学   118371篇
内科学   268589篇
皮肤病学   30813篇
神经病学   108302篇
特种医学   55992篇
外国民族医学   469篇
外科学   213987篇
综合类   39801篇
现状与发展   21篇
一般理论   450篇
预防医学   94962篇
眼科学   32610篇
药学   105807篇
  53篇
中国医学   5963篇
肿瘤学   79636篇
  2018年   13666篇
  2017年   11317篇
  2016年   12290篇
  2015年   14253篇
  2014年   19715篇
  2013年   28254篇
  2012年   37238篇
  2011年   39377篇
  2010年   23657篇
  2009年   22626篇
  2008年   36737篇
  2007年   39884篇
  2006年   40239篇
  2005年   38789篇
  2004年   37306篇
  2003年   36090篇
  2002年   35358篇
  2001年   64874篇
  2000年   66442篇
  1999年   56212篇
  1998年   14531篇
  1997年   13313篇
  1996年   12676篇
  1995年   12633篇
  1994年   11837篇
  1992年   43104篇
  1991年   41580篇
  1990年   40802篇
  1989年   39773篇
  1988年   37140篇
  1987年   36579篇
  1986年   35028篇
  1985年   33205篇
  1984年   24861篇
  1983年   21047篇
  1982年   12649篇
  1981年   11555篇
  1979年   23911篇
  1978年   17040篇
  1977年   14777篇
  1976年   13348篇
  1975年   15231篇
  1974年   18065篇
  1973年   17562篇
  1972年   16817篇
  1971年   15715篇
  1970年   14894篇
  1969年   14337篇
  1968年   13453篇
  1967年   11997篇
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
21.
22.
淫羊藿是一种常用的中药材,淫羊藿苷是从淫羊藿中提取的一种黄酮类化合物,也是淫羊藿中最主要的活性物质。研究发现,淫羊藿苷具有促进成骨细胞的生成和活化、调节免疫、抗衰老和抗炎等多种功能。临床上淫羊藿(苷)用于治疗生殖系统、骨关节系统、呼吸系统、神经系统、心血管系统和免疫系统等多种疾病。淫羊藿(苷)对男性生殖系统的作用及机制主要包括具有雄性激素样作用,促进睾内睾酮的合成和分泌。淫羊藿(苷)通过改善精子发生的微环境、增强睾丸抗氧化作用促进精子生成,增加精子密度,改善精子活力,减缓生殖衰退。此外,淫羊藿(苷)可促进阴茎勃起,治疗勃起功能障碍及早泄。  相似文献   
23.
24.
25.
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.  相似文献   
26.

Objective

Explore the perceived benefits of a Veterans Health Administration (VHA) geriatric specialty telemedicine service (GRECC Connect) among rural, older patients and caregivers to contribute to an assessment of its quality and value.

Data Sources

In Spring 2021, we interviewed a geographically diverse sample of rural, older patients and their caregivers who participated in GRECC Connect telemedicine visits.

Study Design

A cross-sectional qualitative study focused on patient and caregiver experiences with telemedicine, including perceived benefits and challenges.

Data Collection

We conducted 30 semi-structured qualitative interviews with rural, older (≥65) patients enrolled in the VHA and their caregivers via videoconference or phone. Interviews were recorded, transcribed, and analyzed using a rapid qualitative analysis approach.

Principal Findings

Participants described geriatric specialty telemedicine visits focused on cognitive assessments, tailored physical therapy, medication management, education on disease progression, support for managing multiple comorbidities, and suggestions to improve physical functioning. Participants reported that, in addition to prescribing medications and ordering tests, clinicians expedited referrals, coordinated care, and listened to and validated both patient and caregiver concerns. Perceived benefits included improved patient health; increased patient and caregiver understanding and confidence around symptom management; and greater feelings of empowerment, hopefulness, and support. Challenges included difficulty accessing some recommended programs and services, uncertainty related to instructions or follow-up, and not receiving as much information or treatment as desired. The content of visits was well aligned with the domains of the Age-Friendly Health Systems and Geriatric 5Ms frameworks (Medication, Mentation, Mobility, what Matters most, and Multi-complexity).

Conclusions

Alignment of patient and caregiver experiences with widely-used models of comprehensive geriatric care indicates that high-quality geriatric care can be provided through virtual modalities. Additional work is needed to develop strategies to address challenges and optimize and expand access to geriatric specialty telemedicine.  相似文献   
27.
Graefe's Archive for Clinical and Experimental Ophthalmology - To describe and present results after a technique for cataract surgery combined with explantation of an iris-fixated phakic...  相似文献   
28.
29.
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz -  相似文献   
30.
Cognitive Therapy and Research - Individuals with Social Anxiety Disorder (SAD) may be at a higher risk for negative outcomes during the COVID-19 pandemic due to isolation that is both...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号